

Australia

Population 2015

24 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.044 (0.044–0.044)	0.18 (0.18–0.19)
Mortality (HIV+TB only)	<0.01 (0–0.019)	0.02 (0–0.08)
Incidence (includes HIV+TB)	1.4 (1.2–1.7)	6 (5.2–6.9)
Incidence (HIV+TB only)	0.029 (0.024–0.033)	0.12 (0.1–0.14)
Incidence (MDR/RR-TB)**	0.062 (0.039–0.085)	0.26 (0.16–0.35)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.05 (0.029–0.071)	0.64 (0.5–0.78)	0.69 (0.53–0.85)
Males	0.046 (0.03–0.062)	0.71 (0.55–0.86)	0.75 (0.58–0.92)
Total	0.096 (0.069–0.12)	1.3 (1.2–1.5)	1.4 (1.2–1.7)

TB case notifications, 2015

Total cases notified	1 254
Total new and relapse	1 254
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	79%
- % pulmonary	63%
- % bacteriologically confirmed among pulmonary	88%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.03 (0.03–0.04)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	21	2%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			35 (23–48)
Estimated % of TB cases with MDR/RR-TB	3.6% (2.2–5.4)	24% (9.4–45)	
% notified tested for rifampicin resistance	76%	63%	961
MDR/RR-TB cases tested for resistance to second-line drugs			35
Laboratory-confirmed cases		MDR/RR-TB: 37, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 35, XDR-TB: 2	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	79%	1 343
Previously treated cases, excluding relapse, registered in 2014	0%	13
HIV-positive TB cases, all types, registered in 2014	47%	17
MDR/RR-TB cases started on second-line treatment in 2013	86%	21
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	
------------------------------------	--

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse

— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB